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Infection Highlights 
2000-01
Mark H. Wilcox, Editor
Health Press Limited, Oxford, 
UK, 2001 (98 pages) 
This 98-page paperback in the Fast
Facts series contains concise updates
on a diverse group of topics in infec-
tious diseases.  Chapters cover newly
recognized and emerging infectious
diseases problems including Escheri-
chia coli O157:H7, Helicobacter
pylori, and Acinetobacter. Other chap-
ters provide therapeutic updates of a
range of problems including exacerba-
tions of chronic obstructive pulmo-
nary disease, HIV infection, and
onychomycosis.  Most reviews are rel-
evant to the clinician with the excep-
tion of discussions on alternative
treatments for methicillin-resistant
Staphylococcus aureus (MRSA) and
antibiotic-resistance genes in plants.
There are 12 chapters, and most of the
authors are recognized authorities in
their areas. 
Page borders are color-coded by
chapter with matching color schemes
for tables.  Each chapter contains a
table of highlights with headings of
“What’s in,” “What’s out,” and fre-
quently “What’s controversial,” or
“What’s needed.”  This approach
works with variable success. It does
give a reader whose thumbing through
the book a quick look at the major
issues.  But I can imagine authors
struggling with what to include in this
format leading to unhelpful entries
such as “Over-prescribing of conven-
tional antibiotics” under “What’s out”
in a chapter on alternative treatments
for MRSA.  In rapidly changing areas
including HIV therapeutics, what was
“in” at the time of writing is already
“out” or “controversial” by the time of
this review in the fall of 2001. 
The chapters are, for the most part,
well written and factual. The reviews
on  Clostridium difficile diarrhea
(authored by the editor) and E. coli
O157:H7 are especially well done.
Unfortunately, the chapter on HIV
chemotherapy contains a few inexpli-
cable errors. Lopinavir, a protease
inhibitor, is listed as a nucleoside
reverse transcriptase inhibitor in both
a table and the text. The authors also
states that the nucleotide analogs, such
as tenofovir are active in their native
form.  In fact, they are prodrugs that
require phosphorylation by cellular
enzymes.  The HIV chapter is also the
most dated, though I cannot fault the
authors for this, given the dynamic
nature of the field.
The editor does not tell us the
intended audience for the book, but it
appears to be geared for the infectious
disease specialist rather than the gen-
eralist.  The reviews average about six
small pages of text, and the discus-
sions are not sufficiently complete to
serve as a background source for the
uninitiated.  The editor writes that
review articles are often unwieldly or
out-of-date at the time of publication.
This text aims to summarize new
information concisely.  Concise it is –
but perhaps too much so, as I came
away from reading many of the
reviews longing for more depth.
Nonetheless, this volume generally
succeeds with providing “fast facts” in
a well-written and easy to read format.
James P. Steinberg
Emory University School of Medicine, 
Atlanta, Georgia, USA
Remote Sensing 
and Geographic 
Information Systems in 
Epidemiology
Simon I. Hay, 
Sarah E. Randolph, 
and David J. Rogers, Editors
Academic Press, London, 2000 
(357 pages) 
The applications of remote sensing
and geographic information systems
(GIS) to vector-borne and helminthic
diseases have progressed far beyond
the pretty pictures which dominated
their early use. As Wood et al. indicate
in the last chapter, the number of
papers in the area has increased drasti-
cally over the last decade, in number
and sophistication. The editors of this
special volume of Advances in Parasi-
tology have been in the forefront of
applying statistical and biological
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The conference is sponsored by the National Foundation for Infectious Dis-
eases (NFID) in collaboration with the CDC and eight other national agencies,
institutes, and organizations involved in conducting or promoting research, pre-
vention, and control of antimicrobial resistance.
The deadline for online submission of abstracts for oral and poster presenta-
tions is April 15, 2002. Registration fee is $350 until May 17. After that date, the
registration fee will be $400.
For additional information, contact NFID, 4733 Bethesda Avenue, Suite 750,
Bethesda, MD 20814-5278; telephone: 301-656-0003; ext. 19; fax: 301-907-
0878; e-mail: resistance@nfid.org. Program announcements and forms for
abstract submission, registration, and hotel reservations are also available at
http://www.nfid.org/conferences/resistance02